The Zhitong Finance App learned that Kang Fang Biotech (09926) is now up more than 4%. As of press release, it has risen 3.97% to HK$48.5, with a turnover of HK$125 million.
According to the news, the positive analysis results of the phase III clinical study of Kangfang Biotech's core product, cardonil combined chemotherapy for first-line gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, were published in an oral report at the 2024 American Cancer Association Annual Meeting (AACR). The overall data was impressive.
Guotai Junan pointed out that data shows that cardonil has the benefit advantage of the entire population and is expected to drive the evolution of the gastric cancer treatment pattern. Currently, the first-line gastric cancer indication of cardonil is in the NDA stage; the first-line cervical cancer indication has reached the PFS end point, and it is expected to reach the OS endpoint and submit an NDA within 24 years. In addition, the company's core product, Evosi, is developing a number of registered clinical trials around the world.